Sign up for this week’s All Access giveaway here!
Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences ENSC, was a guest on Benzinga’s All Access on Sep 23, 2022.
Ensysce is a biotech company committed to stemming the prescription drug abuse epidemic. The company focuses on innovative chemistry to meet research & development goals. Its approach is to look at drug delivery from a different view, using sophisticated chemistry to change the mode of activation rather than just modify a formulation.
Watch the full interview here:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.